sector medic suppli devic
 thought ahead import call
messag view zimmer upcom earn call import event
stock manag set provid formal guidanc first time
remedi troubl warsaw north manufactur facil enter critic
junctur believ new ceo bryan hanson right emphas long-
term natur turnaround convers street thu far see
week call establish baselin investor sentiment begin improv
move year lower pt maintain
buy rate
first step zimmer turnaround view number stop come
month ago consensu call compani earn
forward today estim come cours
good reason retrench zimmer suppli constraint
last far longer manag predict last summer new leadership
bring revis set invest prioriti good news believ
expect come enough fact think current consensu
outlook leav manag enough wiggl room make necessari invest
busi get back pattern under-promis over-deliv expect
guidanc bracket current street forecast lower ep
estim accur reflect anticip spend level top line
project sale base current fx rate impli organ
growth year
step two resolv situat warsaw north expect mission
accomplish banner front week rather see situat
news good news expect manag reiter prior timelin
return full suppli end quarter note setback could
still occur indic least far execut goal combin
guidanc rang support current consensu outlook view necessari
precondit investor begin feel comfort stori stabil
meanwhil next phase turnaround upgrad portfolio could kick
sooner zimmer current balanc sheet situat would suggest start
write nearli year ago see think zimmer turnaround follow
playbook stabil struggl core busi
divest non-strateg asset use augment balanc sheet capac diversifi
higher growth adjac last month wsj report compani could
consid divestitur dental busi see fit game plan mr hanson
declin comment report back aao march investor confer
look updat topic thursday call shed dental
enough significantli improv zimmer growth trajectori estim
combin remov lag segment effect reinvest proce
could move needl believ movement front would view
posit investor
part continu see path meaning valu creation zimmer
process admittedli slower start hope compani first
announc ceo transit last juli time valu name rel
scarc med-tech like risk/reward zimmer potenti even modest
fundament progress drive improv sentiment out-performance
lower price target take account revis
estim signific upsid potenti target current level reiter
buy rate
page analyst certif import disclosur
zimmer merger biomet made player hip knee wide
margin share global recon sale deal provid compani
ep accret scale also left zimmer sale come slow growth
market underperform late under-perform
exacerb past year chronic manufactur issu suppli constraint
leav zimmer unabl servic client base effect remedi
issu taken far longer manag origin anticip believ
compani posit return normal inventori level drive
improv top line growth profit long-term continu see
opportun addit valu creation commit shed non-cor
asset diversifi higher growth adjac think strateg shift
would view posit street result higher multipl stock
today trade signific discount rest large-cap med-tech group
zimmer share current trade ntm ep estim ntm
ebitda well large-cap med-tech averag view
discount broader group justifi given zimmer inferior top line growth trajectori
vs see current valuat gap excess expect share
re-rat upward market discount possibl new manag drive
growth reacceler lower price target
base multipl revis forward ntm ep estim
signific upsid potenti target current level assign zimmer share
buy rate
downsid risk rate includ failur attract talent new leadership and/or
implement strateg shift drive sustain valu creation increas price and/or
volum pressur ortho implant manufactur bundl payment initi
greater anticip share loss recon due linger suppli constraint
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
figur annual revenu build pro forma bmet deal jan
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
